Association of differential gene expression with imatinib mesylate and omacetaxine mepesuccinate toxicity in lymphoblastoid cell lines

• Príomhchruthaitheoirí: Kulkarni Hemant (Údar), Göring Harald H H (Údar), Diego Vincent (Údar), Cole Shelley (Údar), Walder Ken R (Údar), Collier Greg R (Údar), Blangero John (Údar), Carless Melanie A (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: BMC, 2012-08-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

<p>Abstract</p> <p>Background</p> <p>Imatinib mesylate is currently the drug of choice to treat chronic myeloid leukemia. However, patient resistance and cytotoxicity make secondary lines of treatment, such as omacetaxine mepesuccinate, a necessity. Given that drug cyto...